Merck Steps up as 'Meaningful Competitor' To Gilead with HIV Pill Approval

Why It Matters

Idvynso expands therapeutic options in a market dominated by Gilead, offering Merck a foothold in HIV while cushioning future earnings as its flagship cancer drug faces patent cliffs.

Key Takeaways

• Idvynso approved for virologically suppressed HIV‑1 adults
• Single‑pill regimen replaces multi‑drug combos
• Non‑inferior to Biktarvy in head‑to‑head trials
• Gilead’s HIV sales topped $20.8 billion in 2025
• Merck seeks revenue diversification before Keytruda loss of exclusivity

Pulse Analysis

Merck’s Idvynso marks a notable entry into the HIV‑1 treatment arena, offering a complete, once‑daily pill that eliminates the need for co‑administration with other antiretrovirals. The FDA’s decision rests on two randomized, active‑controlled studies that showed patients switching from Biktarvy maintained viral suppression at rates comparable to those staying on their existing regimen. By targeting virologically suppressed adults without prior treatment failures, Idvynso positions itself as a convenient anchor therapy for a broad patient segment.

The HIV market has long been dominated by Gilead, whose 2025 HIV sales reached $20.8 billion, driven largely by the blockbuster Biktarvy. While analysts acknowledge Idvynso’s potential to broaden therapeutic diversity, they caution that Gilead’s entrenched prescribing habits and recent launch of Yeztugo—a twice‑yearly prophylactic—limit the new drug’s immediate market share. BMO Capital Markets projects only limited erosion of Gilead’s revenues, suggesting Idvynso will serve more as a niche alternative than a disruptive force.

Beyond the HIV space, Idvynso’s approval aligns with Merck’s strategic push to offset the looming decline of Keytruda, its top‑selling oncology product that generated $31.7 billion in 2025. With Keytruda’s patent protection set to weaken around 2028‑2033, Merck anticipates up to $22 billion in additional sales by diversifying its pipeline. Idvynso thus not only expands Merck’s infectious‑disease portfolio but also provides a revenue buffer as the company navigates the inevitable post‑patent landscape.